GYRE HealthcareBeta data

Gyre Therapeutics, Inc.

$4.44-6.13%

Price as of close on Nov 3, 2026 · Financials updated Oct 9, 2026

Basics

Sector: Healthcare
Industry: Biotechnology
Country: United States
Market cap: 470.8M USD
Enterprise value: 456.4M USD
Full-time employees: 625

Overall health

Drawback: less profitable than most peersless profitable than peers
Drawback: growing more slowly than most peersgrowing more slowly than peers
Drawback: its shares are priced higher than most peers relative to what it earnspriced higher than peers for its earnings
Drawback: its share price swings more than most peers’ (beta 4.74 vs a peer median of 0.63)bigger price swings (beta 4.74 vs peers 0.63)
About average: risk (debt, liquidity and share-price swings)risk

Ranks #1,099 of 1,157 healthcare companies (bottom 6%)

See how it ranks against its peers

Worth knowing

Profit growing, cash flow isn't. Profit +129% since 2022, operating cash flow −91%.
Gyre Therapeutics's reported profit rose 129% since 2022, but the cash its operations generate changed −91%. When profit and cash diverge like this, it's worth understanding why (for example, customers paying more slowly or gains that aren't cash).Gyre Therapeutics's reported profit rose 129% since 2022, but the cash its operations generate changed −91%. When profit and cash diverge like this, it's worth understanding why.
Shareholders being diluted. Shares outstanding up 75% from December 2022 to August 2026.
Gyre Therapeutics had 75% more shares at August 2026 than at December 2022, mostly from issuing stock (for pay, acquisitions or fundraising). Each existing share now owns a smaller slice of the business.Gyre Therapeutics had 75% more shares at August 2026 than at December 2022, mostly from issuing stock. Each existing share now owns a smaller slice of the business.
Valuation signals disagree. Cheaper than 50% of peers on free cash flow, but only 0% on earnings.
Relative to its free cash flow, Gyre Therapeutics looks cheaper than 50% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.
Not profitable yet. Reported a loss over the last 12 months.
Gyre Therapeutics reported a net loss over the last twelve months, so earnings-based measures can't show it as cheap.

StockQuotient Score

21/ 100

Oct 5 24 → Nov 4 21 (-3)

Fundamentals: Yahoo Finance, not primary filings

Valuation

Is the price right?

8/100

Weak

3/3 inputs reported · High confidence

Since last quarter: ▼ Weaker

Share count up 14.9% (existing holders diluted)

Valuation also moves with the share price every day.

Why

Weaker than most peers on:

▼ Earnings yield
▼ EBITDA yield

Compare with peers

Behind the score

Sector-normalized EBITDA, earnings, and free cash flow yields.

Earnings yield-5.6%

Yahoo Finance · trailing 12 monthsNegative (a loss or cash outflow), so it counts as zero whatever the share price30% base weight · Z-score -1.00Sector median: 0.0148 · MAD: 0.0148

EBITDA yield-2.7%

Yahoo Finance · trailing 12 monthsNegative (a loss or cash outflow), so it counts as zero whatever the share price50% base weight · Z-score -1.00Sector median: 0.0401 · MAD: 0.0401

Free cash flow yield-1.5%

Yahoo Finance · trailing 12 months · operating cash flow − capital spendingNegative (a loss or cash outflow), so it counts as zero whatever the share price20% base weight · Z-score 0.00Sector median: 0.0000 · MAD: 0.0000

Other data (not scored)

Book yield22.9%

Yahoo FinanceReported valueInformational · 0% composite weightSector median: 0.3716 · MAD: 0.2313

Growth

Is it growing?

18/100

Weak

3/3 inputs reported · High confidence

Since last quarter: ▼ Weaker

12-month revenue fell 6.2%

Why

Weaker than most peers on:

▼ EPS growth
▼ Revenue growth

Compare with peers

Behind the score

Revenue and earnings-per-share growth over one year, and revenue growth over three years.

Earnings per share growth-60.0%

Yahoo Finance · fiscal year to Dec 2025Reported value33% base weight · Z-score -2.33Sector median: 0.0976 · MAD: 0.2991

3-year revenue growth4.5%

Yahoo Finance · 3 fiscal years to Dec 2025Reported value33% base weight · Z-score -0.16Sector median: 0.0584 · MAD: 0.0840

Revenue growth-3.4%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score -0.97Sector median: 0.0609 · MAD: 0.0974

Profitability

Does it earn well?

23/100

Weak

3/3 inputs reported · High confidence

Since last quarter: ▼ Weaker

Operating margin fell 20.1 points to -20.2%
Free cash flow turned negative over the last 12 months

Why

Weaker than most peers on:

▼ ROIC
▼ Operating margin
▼ ROA

Compare with peers

Behind the score

Return on invested capital, operating margin, and return on assets.

Operating margin-20.2%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score -2.24Sector median: 0.0706 · MAD: 0.1217

Return on assets-14.2%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score -2.95Sector median: 0.0166 · MAD: 0.0537

Return on invested capital-27.1%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score -3.17Sector median: 0.0471 · MAD: 0.1004

Other data (not scored)

Gross margin93.8%

Yahoo Finance · trailing 12 monthsOutlier capped at sector 5th/95th percentileInformational · 0% composite weightSector median: 0.4697 · MAD: 0.2310

Return on equity-17.4%

Yahoo Finance · trailing 12 monthsReported valueInformational · 0% composite weightSector median: 0.0330 · MAD: 0.1225

Risk

Debt, liquidity, price swings

Moderate

Moderate relative risk

3/3 inputs reported · High confidence

Since last quarter: No major change

Why

Mixed versus peers:

▲ Debt / equity
▲ Current ratio
▼ Beta

Compare with peers

Behind the score

Relative to sector peers: 0 = lower relative risk · 1 = moderate · 2 = higher. Based on leverage, beta and liquidity.

Beta4.74

Yahoo Finance · 5-year monthly beta vs the marketOutlier capped at sector 5th/95th percentile33% base weight · Z-score -4.28Sector median: 0.6250 · MAD: 0.3380

Current ratio4.26×

Yahoo FinanceReported value33% base weight · Z-score 1.21Sector median: 2.5860 · MAD: 1.3850

Debt / equity0.02×

Yahoo FinanceReported value33% base weight · Z-score 0.98Sector median: 0.2215 · MAD: 0.2039

Valuation, growth and profitability scores: higher is better. Risk: 0 is lower, 2 is higher. Risk is a relative proxy, not a bankruptcy probability. Scores depend on available sector peers.

Questions investors ask about Gyre Therapeutics

Is Gyre Therapeutics getting weaker?: Its latest SEC filing (Aug 7, 2026) got weaker in some ways: operating margin fell 20.1 points to -20.2%; 12-month revenue fell 6.2%. Its overall score is unchanged at 21/100 since Oct 28, 2026.
How is Gyre Therapeutics valued vs its peers?: Priced higher than most peers relative to what it earns. Valuation scores 8/100 against 1,393 healthcare peers. Earnings yield -5.6% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -5.6% vs peers 1.5% (weaker than 100% of peers).
Is Gyre Therapeutics growing?: More slowly than most of its peers. Growth scores 18/100 against 1,393 healthcare peers. Earnings per share growth -60.0% vs a peer median of 9.8% (weaker than 94% of peers).Earnings per share growth -60.0% vs peers 9.8% (weaker than 94% of peers).
How profitable is Gyre Therapeutics?: Less profitable than most of its peers. Profitability scores 23/100 against 1,393 healthcare peers. Return on invested capital -27.1% vs a peer median of 4.7% (weaker than 82% of peers).Return on invested capital -27.1% vs peers 4.7% (weaker than 82% of peers).
How risky is Gyre Therapeutics?: Moderate risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Debt / equity 0.02× vs a peer median of 0.22× (stronger than 84% of peers).Debt / equity 0.02× vs peers 0.22× (stronger than 84% of peers). Beta 4.74 vs a peer median of 0.63 (weaker than 100% of peers).Beta 4.74 vs peers 0.63 (weaker than 100% of peers). A relative measure, not a bankruptcy probability.

Latest filing: what changed

Quarter ended Jun 30, 2026 · filed Aug 7, 2026 · compared with the quarter ended Mar 31, 2026

Got weaker

Operating margin fell 20.1 points to -20.2%
12-month revenue fell 6.2%
Share count up 14.9% (existing holders diluted)
Free cash flow turned negative over the last 12 months

	Previous quarter	Latest quarter	Change
Revenue (12 months)	117.0M USD	109.8M USD	−6.2%
Net income (12 months)	−3.7M USD	−28.2M USD	+660.2%
Operating margin	-0.1%	-20.2%	−20.1 pts
Free cash flow (12 months)	3.1M USD	−6.1M USD	turned negative
Cash	37.5M USD	43.3M USD	+15.4%
Shares outstanding	97.0M	111.5M	+14.9%

From the company’s own SEC filings, as filed. Twelve-month figures roll forward one quarter at a time.

Industry valuation context

Industry: Biotechnology · 132 companies

Valuations in Biotechnology are within their usual range since 2016.

48% of months since 2016 were valued lower than now.
22% of companies are in the most expensive fifth of their own price-to-sales history.
Median price-to-sales is +530% vs the whole market, against a usual +637%.

2016Shaded: most expensive fifth of its range2026

Earnings-based measures are left out for now because many companies in Biotechnology are losing money.

Financials

Fiscal years from SEC annual filings · change vs the prior year

Key ratios	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	Change
Gross margin	—	95.3%	95.9%	96.3%	—	—
Operating margin	-1197.8%	9.0%	-59.3%	15.3%	9.9%	▼ 5.4 pts
Net margin	-1198.3%	4.2%	-75.3%	16.9%	8.5%	▼ 8.4 pts
Return on assets (ROA)	-158.0%	5.1%	-73.3%	14.3%	5.9%	▼ 8.3 pts
Return on equity (ROE)	-214.0%	10.1%	—	28.3%	9.3%	▼ 19 pts
Free cash flow margin	-1152.8%	5.6%	15.3%	-5.6%	-0.2%	▲ 5.5 pts
Current ratio	3.63×	4.06×	2.85×	3.32×	5.60×	▲ 69%
Quick ratio	—	3.56×	2.64×	2.99×	5.44×	▲ 82%

GYRE price history

Price history is added with the daily price update and will appear after the next one.

Similar companies

Sector leaderboards

BB Biotech AGBBZA.DE100/ 100

Arbutus Biopharma CorporationABUS97/ 100

Q32 Bio Inc.QTTB97/ 100

Bringing the fundamentals into focus…

Overall health

Drawback: less profitable than most peersless profitable than peers

Drawback: growing more slowly than most peersgrowing more slowly than peers

Drawback: its shares are priced higher than most peers relative to what it earnspriced higher than peers for its earnings

Drawback: its share price swings more than most peers’ (beta 4.74 vs a peer median of 0.63)bigger price swings (beta 4.74 vs peers 0.63)

About average: risk (debt, liquidity and share-price swings)risk

Ranks #1,099 of 1,157 healthcare companies (bottom 6%)

See how it ranks against its peers

Worth knowing

Profit growing, cash flow isn't. Profit +129% since 2022, operating cash flow −91%.

Gyre Therapeutics's reported profit rose 129% since 2022, but the cash its operations generate changed −91%. When profit and cash diverge like this, it's worth understanding why (for example, customers paying more slowly or gains that aren't cash).Gyre Therapeutics's reported profit rose 129% since 2022, but the cash its operations generate changed −91%. When profit and cash diverge like this, it's worth understanding why.

Shareholders being diluted. Shares outstanding up 75% from December 2022 to August 2026.

Gyre Therapeutics had 75% more shares at August 2026 than at December 2022, mostly from issuing stock (for pay, acquisitions or fundraising). Each existing share now owns a smaller slice of the business.Gyre Therapeutics had 75% more shares at August 2026 than at December 2022, mostly from issuing stock. Each existing share now owns a smaller slice of the business.

Valuation signals disagree. Cheaper than 50% of peers on free cash flow, but only 0% on earnings.

Relative to its free cash flow, Gyre Therapeutics looks cheaper than 50% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.

Not profitable yet. Reported a loss over the last 12 months.

Gyre Therapeutics reported a net loss over the last twelve months, so earnings-based measures can't show it as cheap.

Questions investors ask about Gyre Therapeutics

Is Gyre Therapeutics getting weaker?

Its latest SEC filing (Aug 7, 2026) got weaker in some ways: operating margin fell 20.1 points to -20.2%; 12-month revenue fell 6.2%. Its overall score is unchanged at 21/100 since Oct 28, 2026.

How is Gyre Therapeutics valued vs its peers?

Priced higher than most peers relative to what it earns. Valuation scores 8/100 against 1,393 healthcare peers. Earnings yield -5.6% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -5.6% vs peers 1.5% (weaker than 100% of peers).

Is Gyre Therapeutics growing?

More slowly than most of its peers. Growth scores 18/100 against 1,393 healthcare peers. Earnings per share growth -60.0% vs a peer median of 9.8% (weaker than 94% of peers).Earnings per share growth -60.0% vs peers 9.8% (weaker than 94% of peers).

How profitable is Gyre Therapeutics?

Less profitable than most of its peers. Profitability scores 23/100 against 1,393 healthcare peers. Return on invested capital -27.1% vs a peer median of 4.7% (weaker than 82% of peers).Return on invested capital -27.1% vs peers 4.7% (weaker than 82% of peers).

How risky is Gyre Therapeutics?

Moderate risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Debt / equity 0.02× vs a peer median of 0.22× (stronger than 84% of peers).Debt / equity 0.02× vs peers 0.22× (stronger than 84% of peers). Beta 4.74 vs a peer median of 0.63 (weaker than 100% of peers).Beta 4.74 vs peers 0.63 (weaker than 100% of peers). A relative measure, not a bankruptcy probability.

Previous quarter

Latest quarter

Change

Revenue (12 months)

117.0M USD

109.8M USD

−6.2%

Net income (12 months)

−3.7M USD

−28.2M USD

+660.2%

Operating margin

-0.1%

-20.2%

−20.1 pts

Free cash flow (12 months)

3.1M USD

−6.1M USD

turned negative

Cash

37.5M USD

43.3M USD

+15.4%

Shares outstanding

97.0M

111.5M

+14.9%

Key ratios

FY 2021

FY 2022

FY 2023

FY 2024

FY 2025

Change

Gross margin

—

95.3%

95.9%

96.3%

—

Operating margin

-1197.8%

9.0%

-59.3%

15.3%

9.9%

▼ 5.4 pts

Net margin

-1198.3%

4.2%

-75.3%

16.9%

8.5%

▼ 8.4 pts

Return on assets (ROA)

-158.0%

5.1%

-73.3%

14.3%

5.9%

▼ 8.3 pts

Return on equity (ROE)

-214.0%

10.1%

—

28.3%

9.3%

▼ 19 pts

Free cash flow margin

-1152.8%

5.6%

15.3%

-5.6%

-0.2%

▲ 5.5 pts

Current ratio

3.63×

4.06×

2.85×

3.32×

5.60×

▲ 69%

Quick ratio

—

3.56×

2.64×

2.99×

5.44×

▲ 82%